Hims & Hers Health, Inc. (BKK:HIMS03)
Thailand · Delayed Price · Currency is THB | Market Cap | 114.20B -76.5% |
| Revenue (ttm) | 74.04B +59.0% |
| Net Income | 4.05B +1.8% |
| EPS | 16.16 -3.7% |
| Shares Out | n/a |
| PE Ratio | 28.21 |
| Forward PE | 12.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,434 |
| Average Volume | 8,858 |
| Open | 2.540 |
| Previous Close | 2.620 |
| Day's Range | 2.520 - 2.560 |
| 52-Week Range | 2.560 - 2.620 |
| Beta | n/a |
| RSI | n/a |
| Earnings Date | May 4, 2026 |
About Hims & Hers Health
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and de... [Read more]
News
Novo and Hims resolve dispute, will sell obesity drugs together, Bloomberg News reports
Wegovy maker Novo Nordisk plans to sell its weight-loss drugs on Hims & Hers Health platform, bringing an end to a dispute between the two companies that escalated into a legal battle last mon...
YieldMax® HIMS Option Income Strategy ETF (HIYY) Trading Halt
MILWAUKEE, March 05, 2026 (GLOBE NEWSWIRE) -- Tidal Investments LLC (“Tidal”) announces that the YieldMax® HIMS Option Income Strategy ETF (NYSE Arca: HIYY) was halted to allow Tidal to evaluate the a...
Hims & Hers Health: Leaving GLP-1s Behind
Hims & Hers (HIMS) remains a 'Strong Buy' at $16, with fair value estimated at $22 despite recent headwinds. International expansion via the $1.15B Eucalyptus acquisition and product diversification a...
Hims' pharmacy partner will reintroduce GLP-1 pill pulled from market, Endpoints News reports
Hims & Hers Health's pharmacy partner, Strive Pharmacy, plans to resume sales of its compounded weight‑loss pill through other healthcare providers after halting distribution following U.S. regulato...
Hims & Hers Health, Inc. (HIMS) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Hims & Hers Health, Inc. (HIMS) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript
Carillon Eagle Small Cap Growth Fund Q4 2025 Portfolio Review
Coherent is expected to continue to benefit from a transition to products that enable faster throughput speeds, while prior constraints on manufacturing capacity appear to be alleviating. BrightSpring...
Glancy Prongay Wolke & Rotter LLP Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it is investigating potential claims against the board of director...
Hims expansion may not come in time for risky GLP-1 business
Telehealth company Hims & Hers Health , known for its weight-loss drug business, is promising it can diversify away from its reliance on compounded GLP-1 sales in the U.S., but that may not happen soo...
HIMS Core Business Faces Challenges in Guidance, GLP-1 Prices & NVO
Forward-looking guidance initially plagued Hims & Hers (HIMS) shares, says Christine Short, though she believes leadership did a good job at "refocusing" goals. She points to the company's businesses ...
Law Offices of Howard G. Smith Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces it is investigating potential claims against the board of directors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE...
The Law Offices of Frank R. Cruz Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) conce...
Hims & Hers Health: The GLP-1 Party Is Over
Hims & Hers Health, Inc. is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. HIMS' reliance on compounded GLP-1 drugs has faltered, with regulatory ...
Hims & Hers Health: Don't Get Lost In The Weeds
Hims & Hers Health, Inc. remains ultra Bullish despite a near 80% drawdown from 52-week highs, with growth initiatives firmly on track. HIMS projects 2026 revenues of $2.7–$2.9 billion, above consensu...
Hims & Hers Health: Great Vision, Now On Sale -- Here's Why I'm Upgrading
Hims & Hers Health, Inc. faces severe volatility, regulatory scrutiny, and legal risks, especially in its weight-loss drug segment, yet I maintain a cautious BUY rating. Q4 results showed revenue of $...
Hims & Hers Health Analysts Cut Their Forecasts After Q4 Results
Hims & Hers Health Inc (NYSE: HIMS) reported mixed financial results for the fourth quarter after the market close on Monday.
KDP Beats & HIMS Misses Sales, QCOM Gains on Upgrades
Keurig Dr. Pepper (KDP) didn't fizzle out when it came to earnings, with Diane King Hall noting a beat Tuesday morning. Hims & Hers (HIMS) couldn't do the same as the telehealth company sees headwinds...
Hims & Hers Health After The GLP-1 Collapse
Hims & Hers Health's revenue grew 59% to $2.35B in 2025, while adjusted EBITDA surged nearly 80% to $318M. Operating cash flow reached $300M, with $929M in liquidity, reinforcing balance sheet strengt...
Hims & Hers Stock Stumbles - Cautions About Pressure Due To Super Bowl Ad, Change In Shipping Cadences
The stock's decline follows a report that revealed revenue missed analyst expectations, adding pressure as broader markets experienced slight gains on the previous trading day.
Wall Street Breakfast Podcast: FedEx Demands Tariffs Return To Sender
FedEx (FDX) is suing the U.S. for a full refund of IEEPA tariffs after a Supreme Court ruling, with potential industry-wide implications. Hims & Hers Health (HIMS) disclosed an SEC investigation into ...
Hims & Hers Q4 Earnings Show Growth Amid GLP-1 Scrutiny
Hims & Hers Health delivered strong FY25 results with 59% revenue growth to $2.35B and 13% subscriber growth, but faces near-term margin pressure. Management guided FY26 revenue of $2.7–$2.9B and Adju...
Hims & Hers Health, Inc. (HIMS) Q4 2025 Earnings Call Transcript
Hims & Hers Health, Inc. (HIMS) Q4 2025 Earnings Call Transcript
Hims & Hers' expansion plans — as well as its Super Bowl ad — have investors worried about profits
The wellness platform's results arrived amid heightened legal and regulatory scrutiny over its weight-loss-drug business.
Hims & Hers Health Fourth-Quarter Profit Falls Despite Higher Revenue
The telehealth platform posted a quarterly profit of $20.6 million, down from $26 million a year earlier.
Hims & Hers Health Reports Mixed Q4 Earnings, Subscribers Cross 2.5 Million
Hims & Hers Health reported fourth-quarter revenue of $617.82 million, missing analyst estimates of $619.22 million. The company reported fourth-quarter earnings of eight cents per share, beating esti...
Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors.
Hims & Hers, the telehealth provider best known for its compounded weight-loss drugs, issues a weak outlook.